{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-118092","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.045177+00:00","generated_at":"2026-06-08T03:21:51.243522+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fortress Biotech raises $10M via public offering of 5.9M units at $1.70/unit","bullets":["Sold 5,885,000 units at $1.70/unit, each consisting of one share common stock and one warrant (exercise $1.70, 5-year term).","Gross proceeds ~$10.0M; net proceeds for operations including R&D, clinical trials, manufacturing, working capital.","Directors and officers purchased ~$2.9M of units in the offering.","Warrants contain anti-dilution adjustment: if dilutive issuance below current exercise price, exercise price reduces to that lower price (one-time).","Offering closed November 14, 2023; Roth Capital acted as exclusive placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-118092","json":"https://secwatch.observer/filing/0001104659-23-118092.json","markdown":"https://secwatch.observer/filing/0001104659-23-118092.md","text":"https://secwatch.observer/filing/0001104659-23-118092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/0001104659-23-118092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/tm2330640d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:21:51.243522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20cfd3b1bad0bbc09158bdc960b5bc9d36d97fee","claim":"Fortress Biotech, Inc. entered into Securities Purchase Agreement with the purchasers party thereto valued at approximately $10.0 million (effective 2023-11-10).","evidence_excerpt":"a Securities Purchase Agreement (the “ Securities Purchase Agreement ”), dated November 10, 2023, between the Company and the purchasers party thereto.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/0001104659-23-118092-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers party thereto"},{"label":"Value","value":"approximately $10.0 million"},{"label":"Effective","value":"2023-11-10"}],"fact_type":"material_agreement"},{"claim_id":"e375bb6d40d8bed2887ee9e6845b6662f40645bb","claim":"Fortress Biotech, Inc. entered into Placement Agent Agreement with Roth Capital Partners, LLC valued at 7.0% of the aggregate gross proceeds (effective 2023-11-10).","evidence_excerpt":"a Placement Agent Agreement, dated as of November 10, 2023, between the Company and Roth (the “ Placement Agent Agreement ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923118092/0001104659-23-118092-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Value","value":"7.0% of the aggregate gross proceeds"},{"label":"Effective","value":"2023-11-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}